Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Clinical trial NCT07193394 · RECRUITING

Trial details

NCT number: NCT07193394
Sponsor: Institut Curie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer

Start date: 2026-01-31
Primary completion: 2028-12-07
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.